Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined with Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial

Key Points

• The aim is to evaluate the efficacy and safety of Toripalimab combined with chemotherapy for treating muscle-invasive bladder cancer.
• Phase II clinical trial design
• Combination of Toripalimab with gemcitabine and cisplatin
• Assessment of treatment efficacy and safety
• Biomarker analysis during treatment
• Demonstrated good efficacy of the treatment combination
• Showed a favorable safety profile
• Suggests Toripalimab as a promising candidate for neoadjuvant therapy in muscle-invasive bladder cancer